Compare HRMY & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | PRGO |
|---|---|---|
| Founded | 2017 | 1887 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 1991 |
| Metric | HRMY | PRGO |
|---|---|---|
| Price | $36.78 | $15.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $49.75 | $20.33 |
| AVG Volume (30 Days) | 615.1K | ★ 2.6M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 7.78% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | $825,944,000.00 | ★ $4,281,800,000.00 |
| Revenue This Year | $23.29 | N/A |
| Revenue Next Year | $15.98 | N/A |
| P/E Ratio | $11.58 | ★ N/A |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $12.17 |
| 52 Week High | $40.93 | $30.93 |
| Indicator | HRMY | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 60.02 |
| Support Level | $35.16 | $14.66 |
| Resistance Level | $37.08 | $15.38 |
| Average True Range (ATR) | 1.43 | 0.51 |
| MACD | -0.21 | 0.09 |
| Stochastic Oscillator | 43.22 | 81.19 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.